HUP9904669A2 - A T-BAM(CD40L)technológia terápiás alkalmazása simaizomsejtekkel kapcsolatos betegségek kezelésére - Google Patents

A T-BAM(CD40L)technológia terápiás alkalmazása simaizomsejtekkel kapcsolatos betegségek kezelésére

Info

Publication number
HUP9904669A2
HUP9904669A2 HU9904669A HUP9904669A HUP9904669A2 HU P9904669 A2 HUP9904669 A2 HU P9904669A2 HU 9904669 A HU9904669 A HU 9904669A HU P9904669 A HUP9904669 A HU P9904669A HU P9904669 A2 HUP9904669 A2 HU P9904669A2
Authority
HU
Hungary
Prior art keywords
smooth muscle
cd40l
muscle cells
bam
technology
Prior art date
Application number
HU9904669A
Other languages
English (en)
Inventor
Leonard Chess
Mihail N. Karpusas
Seth Lederman
David W. Thomas
Michael J. Yellin
Original Assignee
Biogen, Incorporated
The Trustees Of Columbia University In The City Of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Incorporated, The Trustees Of Columbia University In The City Of New York filed Critical Biogen, Incorporated
Publication of HUP9904669A2 publication Critical patent/HUP9904669A2/hu
Publication of HUP9904669A3 publication Critical patent/HUP9904669A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)

Abstract

A találmány eljárást ismertet a CD40-hőrdőzó simaizőmsejtek CD40ligandűm (CD40L) által történő aktiválásnak gátlására a sejtekfelületén in vivő és ex vivő. Az eljárás abból áll, hőgy a sejteketegy őlyan szerrel hőzzák érintkezésbe, amely képes meggátőlni a CD40Lés CD40 közötti kölcsönhatás kialakűlását a sejteken. Ismertetik amegfelelő szer tervezésének alapelveit. A CD40-hőrdőzó simaizőmsejtekaktiválásának in vivő gátlása simaizőmsejt-függő betegségek kezelésérehasználható. ŕ
HU9904669A 1996-07-08 1997-07-03 Therapeutic applications of t-bam(cd40l)technology to treat diseases involving smooth muscle cells HUP9904669A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67773096A 1996-07-08 1996-07-08

Publications (2)

Publication Number Publication Date
HUP9904669A2 true HUP9904669A2 (hu) 2000-05-28
HUP9904669A3 HUP9904669A3 (en) 2001-06-28

Family

ID=24719894

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9904669A HUP9904669A3 (en) 1996-07-08 1997-07-03 Therapeutic applications of t-bam(cd40l)technology to treat diseases involving smooth muscle cells

Country Status (20)

Country Link
US (2) US20030219437A1 (hu)
EP (1) EP0956030A4 (hu)
JP (1) JP2000515507A (hu)
CN (1) CN1242809C (hu)
AU (1) AU731299B2 (hu)
BG (1) BG63489B1 (hu)
BR (1) BR9710264A (hu)
CA (1) CA2259962C (hu)
CZ (1) CZ297300B6 (hu)
EA (1) EA004401B1 (hu)
EE (1) EE9900010A (hu)
HU (1) HUP9904669A3 (hu)
IL (1) IL127884A0 (hu)
IS (1) IS4935A (hu)
NO (1) NO990019L (hu)
NZ (1) NZ333602A (hu)
PL (1) PL188408B1 (hu)
SK (1) SK499A3 (hu)
TR (1) TR199900029T2 (hu)
WO (1) WO1998001145A1 (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0110779A (pt) 2000-05-12 2005-01-11 Beth Israel Hospital Composições e métodos para adquirir supressão imunológica
US20020173053A1 (en) * 2001-04-27 2002-11-21 Bassam Damaj Multiple simultaneous antigen detection by immunohistochemistry
ES2263984T3 (es) * 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
UY32802A (es) * 2009-07-23 2011-01-31 Provimi Holding B V Composiciones para reducir la metanogénesis gastrointestinal en rumiantes
TW201741337A (zh) * 2016-05-13 2017-12-01 麥迪紐有限責任公司 ＣＤ４０Ｌ-Ｆｃ融合多肽及其使用方法
KR102019033B1 (ko) * 2016-11-11 2019-09-06 다이노나(주) Cd40에 특이적으로 결합하는 항체 및 그의 용도
US11793854B2 (en) 2019-03-21 2023-10-24 Op-T Llc Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
CA2089229C (en) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6340459B1 (en) * 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US6822070B2 (en) * 1996-03-11 2004-11-23 David Baltimore Truncated CRAF1 inhibits CD40 signaling

Also Published As

Publication number Publication date
TR199900029T2 (xx) 1999-04-21
NO990019L (no) 1999-03-08
CA2259962A1 (en) 1998-01-15
AU4229297A (en) 1998-02-02
AU731299B2 (en) 2001-03-29
BR9710264A (pt) 1999-08-10
BG103148A (en) 1999-10-29
NZ333602A (en) 2000-06-23
PL188408B1 (pl) 2005-01-31
CN1227494A (zh) 1999-09-01
EP0956030A4 (en) 2001-11-28
CZ2699A3 (cs) 1999-05-12
IL127884A0 (en) 1999-10-28
EA004401B1 (ru) 2004-04-29
NO990019D0 (no) 1999-01-04
US20030219437A1 (en) 2003-11-27
WO1998001145A1 (en) 1998-01-15
BG63489B1 (bg) 2002-03-29
CN1242809C (zh) 2006-02-22
CA2259962C (en) 2002-01-22
EP0956030A1 (en) 1999-11-17
CZ297300B6 (cs) 2006-11-15
US20080050369A1 (en) 2008-02-28
IS4935A (is) 1998-12-23
SK499A3 (en) 1999-08-06
EA199900091A1 (ru) 1999-08-26
EE9900010A (et) 1999-06-15
HUP9904669A3 (en) 2001-06-28
JP2000515507A (ja) 2000-11-21
PL331104A1 (en) 1999-06-21

Similar Documents

Publication Publication Date Title
NZ337211A (en) Method of treating inflammatory, HIV diseases by using peptidyl boronic acid ester and acid compounds as proteasome inhibitors
TR199802676A2 (xx) T�m�rlerin, t�m�rle ilgili hastal�klar�n ve ka�eksinin tedavisi ve �nlenmesi i�in y�ntem.
EP1231914A4 (en) NORDIHYDROGUAIARTIC DERIVATIVES FOR USE IN THE TREATMENT OF TUMORS
ZA95463B (en) Use of interleukin-12 to prevent graft-versus-host disease
DK0912192T3 (da) Administration af GM-CSF til behandling af hjernetumorer og forebyggelse af sådanne tumorers tilbagevenden
HUP9904669A2 (hu) A T-BAM(CD40L)technológia terápiás alkalmazása simaizomsejtekkel kapcsolatos betegségek kezelésére
IS2254B (is) Meðhöndlun á risaeitlingasarkmeini með tálmum viðeitilfrumueiturslóðinni
MX9805724A (es) Aplicaciones terapeuticas de la tecnologia t-bam (cd40-l) para tratar enfermedades inflamatorias del riñon que tienen puntos de iniciacion diferentes de la deposicion de autoanticuerpos.
NO20012569L (no) Anvendelse av aryl-substituerte syklobutylalkylaminer for behandling av urininkontinens
HK1046847A1 (en) Pharmaceutical combination with analgesic action containing paracetamol and buspirone.
AU9183698A (en) A new chemical entity (endipalene) in the treatment of psoriasis
NO984196L (no) FremgangsmÕte for behandling av stoffmisbruk
ZA966698B (en) Use of PDE inhibitors in the treatment of urinary bladder diseases.
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine
UA30501A (uk) Спосіб лікування склеродермії у дітей з утягненням в патологічний процес органів шлунково-кишкового тракту
GEP20002075B (en) Method for Treatment of Pathological Process
UA19645A (uk) Спосіб рефлексотерапії та пристрій для його здійсhеhhя
Rang et al. The Growth Kinetics of Bladder Tumor Following BCG Treatment
NO892474D0 (no) Anordning ved behandling av reumatiske sykdommer, spesielt ved celleregenerering.
JPS549191A (en) Electric active carbon regenerating apparatus
UA10257A (uk) Спосіб фізіотерапевтичного впливу на організм людини
UA37510A (uk) Спосіб лікування загрози передчасного переривання вагітності
JPS52118849A (en) Process for purifying polluted water
RU98115370A (ru) Способ лечения заболеваний щитовидной железы
UA34351A (uk) Спосіб визначення фізичної працездатності людини

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CIT, US

Free format text: FORMER OWNER(S): BIOGEN, INCORPORATED, US

Owner name: BIOGEN IDEC MA, INC., US

Free format text: FORMER OWNER(S): BIOGEN, INCORPORATED, US

FC4A Lapse of provisional application due to refusal